Vaxcyte Catapults Past Pfizer and Merck With a 31-Valent Phase 3 Beat — The $6.5B PCV Franchise Is Now on Notice

On Oct. 5, 2026, Vaxcyte reported positive topline data from OPUS-1, the pivotal Phase 3 trial of VAX-31 in roughly 4,000 adults. The readout hit every pre-specified co-primary immunogenicity endpoint, with VAX-31 meeting non-inferiority on all 28 serotypes shared with Pfizer's Prevnar 20 and Merck's Capvaxive. The lower bound of every 95% confidence interval on the OPA geometric mean ratio cleared the0.667 threshold regulators expect for non-inferiority.

The clinical framing the company has used all along — that 31-valent coverage could deliver 13–36% incremental protection against invasive pneumococcal disease (IPD) and 19–31% incremental protection against pneumococcal pneumonia over standard-of-care PCVs — moves from modeled promise to documented performance. That is what investors paid a 50%-plus premium for on Monday morning.

The Prevnar family brought in roughly $6.49B in 2025 — about 10% of Pfizer's full-year revenue. But the franchise has been sliding for two consecutive quarters: Q3 2025 sales of $1.7B fell 3% year-over-year, and Q2 2026 sales of $1.3B fell another 4% year-over-year. The VAX-31 data lands on a franchise that was already losing share to Capvaxive in adults and to pediatric inertia elsewhere.

Pfizer has been signaling the threat for over a year. In May 2026 the company advanced a next-generation pediatric PCV through Phase 2 and disclosed a 25-valent adult candidate intended to enter clinical development by year-end 2026. Both efforts pre-date the OPUS-1 readout. The implicit message from management was clear: PCV20's 20-valent coverage will not hold the high ground against a 31-valent competitor with documented superiority on three strains.

When Merck launched Capvaxive in mid-2024, the entire marketing pitch was serotype breadth. Twenty-one serotypes, designed specifically for adults, immediately captured share against Prevnar 20. Sales scaled from $50M in Q4 2024 to $244M in Q2 2025. A pediatric expansion in June 2026, based on the STRIDE-13 trial, was meant to extend the franchise into high-risk kids.

OPUS-1 reduces that pitch to 'ten fewer serotypes.' VAX-31 hit non-inferiority on 17 of 19 shared serotypes with Capvaxive, collapsing Merck's serotype advantage from +1 to −10 in a single readout. The two serotypes where VAX-31 missed the strict 0.667 threshold —3 and 12F — are both contained in Capvaxive, but the historical 0.5 margin regulators accepted for past PCVs still cleared. For label purposes, this is essentially a non-issue; for marketing, it is.

Merck's broader vaccine economics — which include Gardasil, Vaxneuvance, M-M-R II and the pneumococcal franchise — already moved from $2,607M in Q2 2025 to $2,361M in Q2 2026. Capvaxive alone scaled from $244M in Q2 2025 to $184M in Q3 2025 (the most recently disclosed quarter before OPUS-1). A31-valent competitor with documented superiority on three strains threatens the only growth asset in an otherwise declining vaccine book.

Vaxcyte has no commercial infrastructure. The company ended Q2 2026 with $2.51B in cash and investments against a trailing-twelve-month net loss of $1.06B, funding roughly 18–24 months of runway. The 50%+ stock move pushes market cap from $8.4B toward $12.6B, but every dollar of future revenue depends on Lonza executing at the dedicated suite inside its Ibex Dedicate Biopark in Visp, Switzerland, and on Thermo Fisher Scientific standing up a fill-finish facility in North Carolina.

Jefferies values peak VAX-31 sales at $3–6B. Mizuho went to a $90–100 share-price target on Monday and called it 'very difficult to refute' as best-in-class in an $8B-plus market that is still growing. Leerink's label assumption — a 31-valent indication covering 32 serotypes (counting cross-reactive 20B) — would be the broadest PCV label ever granted.

OPUS-1 cleared the regulatory bar. It did not address three remaining questions that will determine whether Vaxcyte keeps the lead or hands it back to Pfizer and Merck.

The short-term setup is unusually clean: two pivotal Phase 3 readouts inside six months of one another, both designed to support the same BLA submission that management has guided to the second half of 2027. The first 12 months of catalyst risk sits on the upside; the next 24 months sit on the manufacturing and competitive side. A 50% stock move prices the Phase 3 win; the BLA filing, the launch, and the share-take in adults will price the actual disruption.

The bear case is real but narrower than the bull case. (1) OPUS-2 or OPUS-3 produces an inconsistent immunogenicity signal — unlikely on the back of OPUS-1 but possible in previously-vaccinated adults. (2) Pfizer's 25-valent program or GSK's 30+ valent candidate leapfrog VAX-31 on breadth before the BLA. (3) Lonza or Thermo Fisher manufacturing constraints limit launch supply into2028. None of these break the OPUS-1 result; all of them compress the commercial case that is now embedded in the share price.